240 related articles for article (PubMed ID: 32966880)
1. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.
Guha A; Addison D; Jain P; Gutierrez JM; Ghosh A; Roddie C; de Lima M; Al-Kindi S; Oliveira GH
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2211-2216. PubMed ID: 32966880
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
[TBL] [Abstract][Full Text] [Related]
3. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy.
Goldman A; Maor E; Bomze D; Liu JE; Herrmann J; Fein J; Steingart RM; Mahmood SS; Schaffer WL; Perales MA; Shouval R
J Am Coll Cardiol; 2021 Nov; 78(18):1800-1813. PubMed ID: 34711339
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
5. Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel.
Dores GM; Jason C; Niu MT; Perez-Vilar S
Am J Hematol; 2021 Sep; 96(9):1087-1100. PubMed ID: 34050534
[TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias.
Gomez-Lumbreras A; Mercadal Vilchez S; Villa-Zapata L; Malone DC; Couriel DR
Leuk Lymphoma; 2023 Dec; 64(13):2071-2080. PubMed ID: 37708442
[TBL] [Abstract][Full Text] [Related]
8. Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study.
Zhai Y; Hu F; Zhu B; Xu J; Guo X; Shi W; Zhou X; Zheng Y; Xu X; Ye X; He J; Xu F
Immunotherapy; 2023 Apr; 15(6):443-456. PubMed ID: 36951157
[TBL] [Abstract][Full Text] [Related]
9. Ocular toxicities in chimeric antigen receptor T-cell therapy: a real-world study leveraging FAERS database.
Zhao N; Hu F; Zhai Y; Ye X; Ruan Y; Liu Z; Wang Z; Shen W; Yuan L
Immunotherapy; 2024 Feb; 16(3):161-172. PubMed ID: 38126138
[TBL] [Abstract][Full Text] [Related]
10. Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years.
Zettler ME; Feinberg BA; Phillips EG; Klink AJ; Mehta S; Gajra A
J Geriatr Oncol; 2021 Mar; 12(2):239-242. PubMed ID: 32798213
[TBL] [Abstract][Full Text] [Related]
11. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
[No Abstract] [Full Text] [Related]
12. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
13. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
15. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
16. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
17. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Pennisi M; Sanchez-Escamilla M; Flynn JR; Shouval R; Alarcon Tomas A; Silverberg ML; Batlevi C; Brentjens RJ; Dahi PB; Devlin SM; Diamonte C; Giralt S; Halton EF; Jain T; Maloy M; Mead E; Palomba ML; Ruiz J; Santomasso B; Sauter CS; Scordo M; Shah GL; Park JH; Yanez San Segundo L; Perales MA
Blood Adv; 2021 Sep; 5(17):3397-3406. PubMed ID: 34432870
[TBL] [Abstract][Full Text] [Related]
18. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
19. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
20. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]